Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 4/20 | 0.41 |
| ▸ | IDH1 | O75874 | 3/20 | 0.38 |
| ▸ | USP1 | O94782 | 3/20 | 0.35 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501791 | 0.94 | P2RX3 (0.38) | P2RX3IDH1USP1IGF1RMAPK8 | |
| SCHEMBL501784 | 0.90 | P2RX3 (0.38) | P2RX3IDH1USP1IGF1RMAPK8 | |
| SCHEMBL10204284 | 0.86 | MAPK1 (0.34) | P2RX3USP1 | |
| SCHEMBL10204421 | 0.86 | KMT2A (0.34) | — | |
| SCHEMBL10204419 | 0.86 | P2RX3 (0.38) | P2RX3 | |
| SCHEMBL10204433 | 0.81 | MAPK1 (0.34) | P2RX3USP1 | |
| SCHEMBL10204337 | 0.80 | IDH1 (0.31) | IDH1 | |
| SCHEMBL6637345 | 0.80 | GAA (0.39) | GAA | |
| SCHEMBL10204262 | 0.80 | KMT2A (0.35) | — | |
| SCHEMBL6086806 | 0.79 | KMT2A (0.34) | P2RX3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106064-B2 | administering 1-[2-Chloro-6-(4-methoxy-benzylamino)-pyridin-4-ylmethyl]-6-(3-[1,3]dioxolan-2-yl-5-methyl-phenoxy)-5-isopropyl-1H-pyrimidine-2,4-dione viricide to treat AIDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-01-31 | — | — | US | disclosed |
| US-8106064-B2 | administering 1-[2-Chloro-6-(4-methoxy-benzylamino)-pyridin-4-ylmethyl]-6-(3-[1,3]dioxolan-2-yl-5-methyl-phenoxy)-5-isopropyl-1H-pyrimidine-2,4-dione viricide to treat AIDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-01-31 | — | — | US | disclosed |
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20080070920-A1 | Novel HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-03-20 | — | — | US | disclosed |
| US-20080070920-A1 | Novel HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLRMT, POLR2H | P2RX3 4157/4885IDH1 633/4885USP1 4201/4885 |
| US-20080070920-A1 | Novel HIV reverse transcriptase inhibitors | POLR2E, POLRMT, POLR2H | P2RX3 4191/4885IDH1 618/4885USP1 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.